Supplementary material to article by M. Inzinger et al. "Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria"

Table SIV. Summary of	treatment	discontinuations	that resulted	
in loss of drug survival				

Reason for treatment	Treatment cycles, $n (\%)^a$			
discontinuation	Adalimumab	Etanercept	Infliximab	
<4 months				
Primary ineffectiveness	15 (44.1)	24 (48)	1(14)	
Loss of initial response	3 (8.8)	2 (4)	0 (0)	
Adverse event	7 (20.6)	8 (16)	3 (43)	
Patient wish	2 (5.9)	5 (10)	0 (0)	
Switch to another biologic agent	1 (2.9)	2 (4)	1 (14)	
Complete remission	1 (2.9)	4 (8)	2 (29)	
Other	5 (14.7)	5 (10)	0 (0)	
Total	34	50	7	
\geq 4 months				
Primary ineffectiveness	34 (23.9)	31 (15.9)	4 (9.8)	
Loss of initial response	42 (29.6)	79 (40.5)	14 (34.1)	
Adverse event	10 (7.0)	19 (9.7)	4 (9.8)	
Patient wish	20 (14.1)	31 (15.9)	7 (17.1)	
Switch to another biologic agent	5 (3.5)	10 (5.1)	2 (4.9)	
Complete remission	9 (6.3)	7 (3.6)	4 (9.8)	
Other	22 (15.5)	18 (9.2)	6 (14.6)	
Total	142	195	41	

^aThe percentages refer to the total number of treatment cycles that were discontinued before, at or after 4 months of treatment.